Mediolanum International Funds Ltd Has $23.06 Million Stock Position in Medtronic PLC $MDT

Mediolanum International Funds Ltd increased its position in shares of Medtronic PLC (NYSE:MDT) by 32.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 245,357 shares of the medical technology company’s stock after acquiring an additional 60,172 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Medtronic were worth $23,056,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Oakworth Capital Inc. lifted its position in Medtronic by 33.3% during the 3rd quarter. Oakworth Capital Inc. now owns 1,202 shares of the medical technology company’s stock valued at $114,000 after purchasing an additional 300 shares during the period. Principal Financial Group Inc. lifted its holdings in Medtronic by 17.2% in the third quarter. Principal Financial Group Inc. now owns 1,656,155 shares of the medical technology company’s stock valued at $157,732,000 after buying an additional 242,910 shares during the period. Blake Schutter Theil Wealth Advisors LLC lifted its holdings in Medtronic by 3.7% in the third quarter. Blake Schutter Theil Wealth Advisors LLC now owns 5,670 shares of the medical technology company’s stock valued at $540,000 after buying an additional 200 shares during the period. Northcape Wealth Management LLC boosted its stake in Medtronic by 2.5% in the third quarter. Northcape Wealth Management LLC now owns 21,248 shares of the medical technology company’s stock valued at $2,024,000 after acquiring an additional 514 shares during the last quarter. Finally, Mutual Advisors LLC grew its holdings in Medtronic by 1.4% during the 3rd quarter. Mutual Advisors LLC now owns 42,702 shares of the medical technology company’s stock worth $4,023,000 after acquiring an additional 590 shares during the period. Institutional investors own 82.06% of the company’s stock.

Medtronic Trading Up 1.9%

MDT opened at $102.96 on Friday. The stock has a market capitalization of $131.99 billion, a P/E ratio of 27.75, a P/E/G ratio of 2.66 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The firm’s fifty day simple moving average is $99.60 and its 200 day simple moving average is $95.69.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter last year, the business posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s payout ratio is currently 76.55%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Sanford C. Bernstein raised their price target on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. JPMorgan Chase & Co. increased their target price on Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. Robert W. Baird set a $103.00 price objective on shares of Medtronic in a report on Tuesday, December 16th. Finally, Barclays increased their target price on shares of Medtronic from $111.00 to $116.00 and gave the stock an “overweight” rating in a report on Thursday, January 8th. Fifteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.28.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).